Quο modo a Cupidine, pro bellis amores scribere coactus sitArma gravi numero violentaque bella parabam edere, materia conveniente modis. par erat inferior versus--risisse Cupido dicitur atque unum surripuisse pedem. 'Quis tibi, saeve puer, dedit hoc in carmina iuris? 5 Pieridum vates, non tua turba sumus. quid, si praeripiat flavae Venus arma Minervae, ventilet accensas flava Minerva faces? quis probet in silvis Cererem regnare iugosis, lege pharetratae Virginis arva coli? 10 crinibus insignem quis acuta cuspide Phoebum instruat, Aoniam Marte movente lyram? sunt tibi magna, puer, nimiumque potentia regna; cur opus adfectas, ambitiose, novum? an, quod ubique, tuum est? tua sunt Heliconia tempe? 15 vix etiam Phoebo iam lyra tuta sua est? cum bene surrexit versu nova pagina primo, attenuat nervos proximus ille meos; nec mihi materia est numeris levioribus apta, aut puer aut longas compta puella comas.' 20 Questus eram, pharetra cum protinus ille soluta legit in exitium spicula facta meum, lunavitque genu sinuosum fortiter arcum, 'quod' que 'canas, vates, accipe' dixit 'opus!' Me miserum! certas habuit puer ille sagittas. 25 uror, et in vacuo pectore regnat Amor. Sex mihi surgat opus numeris, in quinque residat: ferrea cum vestris bella valete modis! cingere litorea flaventia tempora myrto, Musa, per undenos emodulanda pedes! 30 ♦ Επρόκειτο να γράψω πολεμικό έπος μα ο Cupido έκλεψε έναν πόδα από το δεύτερο στίχο μου (1-4). Διαμαρτυρήθηκα ότι δεν έχει δικαίωμα να παρεμβαίνει στην ποίησή μου (5-18). Πώς θα μπορούσα να γράψω ελεγείες αφού δεν ήμουν ερωτευμένος; (19-20) Tότε εκείνος μου απάντησε μ' ένα ερωτικό βέλος, επιβάλλοντας έτσι και θέμα για την ποίησή μου (22-24). Τώρα πια είμαι αναγκασμένος να εγκαταλείψω το έπος και να στραφώ στην ελεγεία (25-30). ♦ Στην ερωτική ποίηση το αντικείμενο του πόθου είναι, ούτως ή άλλως, πάντα απόν R. Barthes, Αποσπάσματα Ερωτικού Λόγου Ύστερα από ένα προλογικό τετράστιχο, όπου συστήθηκαν ipsa voce ενώπιον των αναγνωστών τα τρία βιβλία της δεύτερης έκδοσης των Amores, ο Οβίδιος έρχεται στο προσκήνιο μ' ένα ποιητολογικό «μανιφέστο» τριάντα στίχων, όπου αναδιηγείται το 23 H Ρητορική της «Επιγονικότητας» Amores, Liber I περιστατικό της μύησής του στον ερωτικό/ελεγειακό λόγο (discourse). Πρωταγωνιστής του επεισοδίου είναι ο φτερωτός τοξότης Ερωτιδεύς (Cupido), ο οποίος, τη στιγμή ακριβώς που ο ποιητής είναι έτοιμος να δοκιμάσει τις στιχουργικές του δυνάμεις στο πολεμικό έπος, του υπεξαιρεί έναν μετρικό πόδα από τον δεύτερο αρειμάνιο εξάμετρό προσγειώνoντάς τον ανώμαλα σε ελεγειακό έδαφος: Arma gravi numero violentaque bella parabam edere, materia conveniente modis. par erat inferior versus--risisse Cupido dicitur atque unum surripuisse pedem. Η εμφατική πρόταξη των arma και bella στον πρώτο στίχο αποτελεί σαφή ένδειξη για τον αναγνώστη ότι ο Οβίδιος έχει απομνημονεύσει καλά τα δύο προοίμια του Βιργιλίου στο πρώτο (Aen. 1. 1: Arma virumque cano, Troiae qui primus ab oris) και στο έβδομο βιβλίο (Αen. 7. 41: dicam horrida bella) της Αινειάδας αντίστοιχα. 1 Εξίσου χαρακτηριστική δείχνει και η...

Background: Carcinoma of the breast is the second leading cause of malignant pleural effusions. This study reports on the efficacy of mitoxantrone as a sclerosing agent in patients with breast cancer who had a pleural effusion as a direct consequence of metastatic disease.

BackgroundMetastatic involvement of pericardium producing cardiac tamponade is rare. When occurs it is mainly from the lung, breast and the neoplasms of the lymphoreticular system. Hematogenous spread of parotid adenocarcinoma to heart is extremely rare and only two cases have been reported in literature so far.Case presentationWe report an unusual case of a patient with adenocarcinoma of the parotid gland, which presented with cardiac tamponade and was treated urgently with pericardial drainage and intrapericardial injection of cisplatin.ConclusionsOur case demonstrates the possibility of metastatic pericardial involvement and cardiac tamponade in patients with parotid adenocarcinoma. The patient was successfully treated with pericardial drainage and intrapericardial injection of chemotherapeutic agent to control recurrent pericardial effusion.

Thymoma is a primary tumor of the thymus epithelial cells. It may be asymptomatic or accompanied with atypical clinical symptoms or paraneoplastic syndromes, such as myasthenia gravis. The biological behavior of thymomas is unpredictable. The invasion of the capsule or the adjacent tissues is the major diagnostic criterion for the malignant behavior of these tumors. This is an interesting case of thymoma diagnosed by fine-needle aspiration biopsy (FNA) and ThinPrep technique, in a 54-year-old female patient with a history of gastric adenocarcinoma. Cytology of the mediastinum mass revealed a mixed population of epithelial cells and lymphocytes. The tumor was excised and the histopathological examination supported the cytological diagnosis. Thymomas commonly constitute a problem in differential diagnosis of mediastinum masses. FNA biopsy in correlation with ThinPrep technique and immunocytochemistry may play a significant role in clarifying the nature of these lesions and may contribute to the early management and choice of the optimal therapeutic manipulation.

The purpose of this study was to assess the efficacy and safety of mitoxantrone in the palliative treatment of pleural effusions due to breast cancer. 114 patients with a known breast malignancy and recurrent symptomatic pleural effusion referred for chest tube drainage and sclerotherapy were studied. They had received no prior intrapleural therapy and had a predicted survival of >1 month. Survival, complications and response to pleurodesis according to radiographic criteria were recorded. The data are expressed as the mean +/-SEM and the median. The mean age of the entire group was 53,5 +/-2,1 years. The mean volume of effusion drained was 1020 +/-125 ml and the chest tube was removed within 5 days in 82% of patients. There were no deaths related to the procedure. Side effects of chemical pleurodesis included mainly fever, chest pain, nausea and vomiting. At 30 days 64 patients (56,3%) had a complete response (CR) and 30 patients (26,3%) partial response (PR) to pleurodesis (overall response: 82,6%). At 60 days the overall response was 78,5% (CR:53,5%, PR: 25%). The mean survival of the entire population was 15,6 +/-2 months. Mitoxantrone is effective in the treatment of malignant pleural effusion due to breast carcinoma without causing significant local or systemic toxicity.